(NASDAQ: AZN) Astrazeneca's forecast annual revenue growth rate of -1.64% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 7.21%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.38%.
Astrazeneca's revenue in 2025 is $68,496,000,000.On average, 5 Wall Street analysts forecast AZN's revenue for 2025 to be $89,405,695,700,000, with the lowest AZN revenue forecast at $88,219,800,000,000, and the highest AZN revenue forecast at $90,374,475,150,000. On average, 5 Wall Street analysts forecast AZN's revenue for 2026 to be $95,079,912,450,000, with the lowest AZN revenue forecast at $94,019,900,000,000, and the highest AZN revenue forecast at $96,709,890,900,000.
In 2027, AZN is forecast to generate $101,093,800,850,000 in revenue, with the lowest revenue forecast at $98,835,750,000,000 and the highest revenue forecast at $103,148,730,400,000.